A recent study suggests that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle regimens.
Findings released in a major medical journal points out that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments must be informed of the potential of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to original mass within about a year and a half.
Weighing Therapies
The study, which looked at dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.
The team point out that people who shed pounds through diet and exercise usually have a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors propose the mechanism of the jabs explains the heightened rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
An Ongoing Disease?
The NHS recommend the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, due to the likelihood of weight regain, the therapy might need to be ongoing.
This view is supported by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," similar to managing conditions like hypertension.
User Accounts
People who have come off the medication describe a powerful resurgence of hunger.
"It felt as if a switch flipping and I was suddenly starving," recalled one woman.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Use
Figures indicate that millions of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is more common among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while the jabs are potent agents for weight loss, they are not a magic cure and lasting health benefits likely depends on ongoing behavioural management.
